Anti glaucomatoustreatments and ocular surface

##plugins.themes.academic_pro.article.sidebar##

Published Mar 6, 2018
Download
pdf
Vol. 95 No. 7 (2017): Issue Jul 2017

##plugins.themes.academic_pro.article.main##

Houda Lajmi
Wady Ben Jalel
Wassim Hmaied
Amin Zahaf
Besma Ben Achour
Lamia El Fekih

Abstract

Background:the antiglaucomatous treatments interact with the ocular surface and can induce its alteration which may affect the therapeutic results
Aim : to describe the interactions between the ocular surface and anti-glaucoma medications and to propose practical attitudes to prevent and manage this issue.
Methods: a retrospective study about 100 patients with a primary opened angle glaucoma treated with anti-glaucomatous drops containing preservatives. We performed an exhaustive examination of the ocular surface with fluorescein instillation to search superficial punctuate keratitis and to evaluate the break up time. All patients had a Schirmer test I.
Results: our patients were under monotherapy in 46% ,two medications in 36%, three medications in 11% and four medications in 7% .Beta-blockers were statistically related to the conjunctival hyperaemia (p = 0.014), BUT alteration (p = 0.001) and Schirmer test ≤ 5 mm (p = 0.0001). Prostaglandin analogues were statistically related to a Schirmer test ≤ 5 mm (p = 0.02). The use of more than two anti-glaucomatous medications was linked to the severity of the clinical signs.
Conclusions: anti glaucoma drops affect the ocular surface through several mechanisms: allergic reaction, direct and indirect toxicity of the active agents as well as their preservatives. The risk is increased by the prior ocular surface abnormalities in these patients. This disease influences the quality of life and leads to poor adherence to treatment.

Keywords:

glaucoma, ocular surface, antiglaucoma medications, preservative agents, benzalkonium chloride

##plugins.themes.academic_pro.article.details##

References

  1. Van wentC, Brasnua E, HamardA P, Baudouin C,Labbe A. Influence des pathologies de la surface oculaire sur le traitement du glaucome. J Fr Ophtalmol2011 :34 ;230-7
  2. Labbe A, Baudouin C. Le traitement du glaucome chez les patients atteints de syndrome sec oculaire. J Fr Ophtalmol2010 ;33 : 285-90
  3. Leung EW, Medeiros FA, Weinreb RN.Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17: 350-5.
  4. Fechtner RD, Godfrey DG, Budenz D, Stewart J,Stewart W, Jasek M. Prevalence of ocular surface complaints in patients withglaucomausingtopicalintraocular pressure-loweringmedications. Cornea 2010 ; 29 : 618-21.
  5. Garcia-Feijoo J, SampaolesiJR .A multicenterevaluation of ocular surface diseaseprevalence in patients withglaucoma. Clin Ophthalmol 2012;6 :441-6
  6. Erb C, Gast U, Schremmer D. Germanregister for glaucoma patients with dry eye. I. Basic outcomewith respect to dry eye. Graefes Arch Clin ExpOphthalmol2008;246:1593-601
  7. Bresson-Dumont H.Tolérance locale des médications anti glaucomateuses un problème sous-estimé. Bull Soc Belge Ophtalmo 2010;315:47-53
  8. Aydin Kunka S, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical anti glaucomadrugs as monotherapy on the ocular surface: a prospective study.JOphthalmol 2014; 2014:1-8
  9. Van wentC ,AlalwaniaH, BrasnuaE,et al. Évaluation de la sensibilité cornéenne chez les patients traités médicalement pour un glaucome ou une hypertonie oculaire. J Fr Ophtalmol 2011; 34: 684- 90
  10. Martone G, Frezzotti P, TosiGM, et al. An in vivo confocalmicroscopyanalysis of effects of topical anti glaucomatherapywithpreservativeoncorneal innervation and morphology. Am J Ophthalmol 2009;147:725-35
  11. Baratz KH, Nau CB, Winter EJ, et al. Effects of glaucomamedications on cornealendothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatmentstudy. Cornea2006;25:1046-52.
  12. Baudouin C. Detrimentaleffect of preservativesin eyedrops : implications for the treatment of glaucoma. Acta Ophthalmol 2008 ; 86 : 716-26.
  13. Debbasch C, Pisella PJ, Rat P, Warnet JM, Baudouin C. Évaluation de la production radicalaire sur empreintes conjonctivales de patients traités au long cours par des collyres antiglaucomateux ou porteurs de lentilles de contact. J Fr Ophtalmol 2000 ; 23 : 239-44.
  14. Moss SE, Klein R, Klein BE. Prevalence of and riskfactors for dry eye syndrome. Arch Ophthalmol 2000;118:1264-8
  15. Chawla A, MCGalliard JN, Batterbury M. Use of eyedrops in glaucoma: how canwe help to reduce non-compliance? Acta OphthalmolScand 2007;85:464.
  16. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topicalantiglaucomamedication. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1446-54.
  17. Nordmann JP, Auzanneau N, Ricard S,BerdeauxG.Visionrelatedquality of life and topicalglaucomatreatmentsideeffects. Healthqual life outcomes 2003; 1 : 75
  18. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes afterdosing of travoprostpreservedwithsofZia, latanoprostwith 0.02% benzalkoniumchloride, and preservative-free artificialtears. Cornea 2008 ;27:339-4
  19. Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients withglaucoma or ocular hypertension treatedwitheither BAK-preservedlatanoprost or BAK-free travoprost .Clin Ophthalmol2010 ;4 : 1253-61
  20. Realini T. Selective laser trabeculoplasty:areview. J Glaucoma2008; 17 : 497-502